MedTrace Logo

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

NCT05049733 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-06-07

No results posted yet for this study

Summary

The purpose of this study is to examine the pharmacokinetics and pharmacodynamics of a hemp-derived oral product containing cannabidiol (CBD) and cannabidiolic acid (CBD-A) at a 1:1 ratio.

Conditions

  • Cannabis

Interventions

DRUG

CBD 1mg/Kg

Participants will ingest soft gel tablets containing CBD 1mg/Kg

DRUG

CBD 2mg/Kg

Participants will ingest soft gel tablets containing CBD 2mg/Kg

DRUG

CBD 4mg/Kg

Participants will ingest soft gel tablets containing CBD 4mg/Kg

DRUG

Placebo CBD

Participants will ingest soft gel tablets containing placebo for CBD

Sponsors & Collaborators

Principal Investigators

  • Tory Spindle, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-07
Primary Completion
2023-06-01
Completion
2023-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05049733 on ClinicalTrials.gov